ClinicalTrials.gg
CompletedNCT07354477(PENGUIN)Updated Nov 2, 2026

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

A Phase 2 interventional study of QLS-111 Ophthalmic Solution (0.015%) and QLS-111 Ophthalmic Solution (0.075%) in Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG) and Normal Tension Glaucoma (NTG), sponsored by Qlaris Bio, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Qlaris Bio, Inc. · Phase 2, Interventional, and Treatment

Updated Nov 2, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.

Enrollment
267th of 279
9 · median 84
Started
2026
with 18 others
Phase 2
76 of 348
5 open now
Registered
330th of 348
by date

Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 267th largest by enrollment of the 279 interventional ones that give a count, is one of 19 that started in 2026, is one of 76 in phase 2, and was the 330th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 348 studies in Glaucoma, Open-Angle with a site in United States, or all of them as a file.
02

Study summary

Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG

Read the detailed description

Pilot, single-site, prospective study of BID OU dosing of QLS-111 0.015 % for 7 days followed by QLS-111 0.075% BID OU in subjects with NPDR, OAG or NTG. Both eyes (OU) will be dosed. The study is comprised of 4 visits including Screening/Baseline visit, 2 Treatment Period visits over 14 days of IP dosing, and a Post-Treatment visit.

03

Conditions studied

  • Non-proliferative Diabetic Retinopathy (NPDR)
  • Open-angle Glaucoma (OAG)
  • Normal Tension Glaucoma (NTG)

Keywords

  • glaucoma
  • diabetic retinopathy
  • vessel dilation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of mild to moderate OAG, mild to moderate NTG, or stable NPDR in at least one eye.
  • Corrected visual acuity in each eye +1.0 logMAR or better by early treatment diabetic retinopathy study (ETDRS) in each eye (equivalent to 20/200).
  • Able and willing to give signed and follow study instructions.

Exclusion criteria

Exclusion Criteria:

  • History of active ocular disease other than mild to moderate OAG, mild to moderate NTG, or stable NPDR.
  • Patient is using more than 1 ocular hypotensive topical medication for intraocular pressure (IOP) control (prior MIGS and/or laser trabeculoplasty to control IOP is allowed if done at least 3 months from Screening (Visit 1).
  • Use of TO β-blockers (i.e. timolol) within 3 months prior to Screening.
  • Is noncompliant with current ocular anti-hypotensive medications and/or unwilling to be compliant throughout the study.
  • severe retinal disease in either eye that will require treatment during the study (e.g., proliferative diabetic retinopathy, exudative, or severe non-exudative macular degeneration). NOTE: background diabetic retinopathy (BDR) as required for the NPDR subjects is allowed if in the Investigator's opinion the BDR is stable and is expected to remain stable during the duration of the study.
  • Anti-VEGF or TO treatment within 3 months prior to Screening or expected treatment while participating in this study. Prior diabetic macular edema (DME) history is allowed if adequately controlled with treatment (anti-VEGFs and steroids not within last 3 months prior to Screening), regimen is stable, and not expected to change during the study. - Corneal pathologic changes preventing reliable measurement (e.g., scarring, opacity, edema, and bullae) in either eye that would inhibit accurate IOP measurements.
  • Previously diagnosed, clinically significant systemic or psychiatric disease (e.g., myasthenia gravis, hepatic, renal, endocrine, pulmonary, or cardiovascular disorders) which might compromise the study results or subject safety. For the purpose of this study previously diagnosed, clinically significant renal disease that should be excluded from enrollment will be defined as Stages 3-5 kidney disease and/or an estimated (eGFR) of ≤59.
  • Use of calcium channel blockers.
  • Labile hypertension and/or hypotension that is inadequately controlled,
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    QLS-111 Ophthalmic Solution, 2 concentrations (0.015% and 0.075%, concurrent) dosed BID for 7 days

    QLS-111 Ophthalmic Solution, 2 concentrations (0.015% and 0.075%) dosed BID for 7 days (taken 12-hour intervals) OU.

    Drug: QLS-111 Ophthalmic Solution (0.015%) · Drug: QLS-111 Ophthalmic Solution (0.075%)

Interventions

06

What researchers measure

Primary outcomes

  1. Change from Baseline in blood flow to the posterior segment of the eye.

    Ocular imaging will be collected at study visits at baseline, treatment period , and 1 week post-treatment and to evaluate change from baseline in retinal vessel diameter and blood flow.

    Time frame: Days 1 through 22

Other outcomes

  1. Ocular safety

    Ocular safety will be assessed by review of the following: • Ocular adverse events (AEs)

    Time frame: Days 1 through 22

  2. Systemic safety

    Systemic safety will be assessed by review of the following: • Systemic AEs

    Time frame: Days 1 through 22

07

Study locations

1 site
  • Stanford University, Dept. of Ophthalmology
    Palo Alto, California 94303, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Oct 2026, 7 months.

Of 38 industry-sponsored phase 2 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 7 months is below that.

Counting every sponsor, half of 41 studies reached it within 11 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Jan 21, 2026
StartActual
Feb 20, 2026
Primary completionActual
Oct 1, 2026
CompletionActual
Oct 1, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 2, 2026
Enrollment
14 (estimated)→9 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Active, not recruiting→Completed
    Enrollment 14 (estimated)→9 (actual)
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07354477
Lead sponsor
Qlaris Bio, Inc.
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Feb 20, 2026
Primary completion
Oct 1, 2026
Completion
Oct 1, 2026
Last update
Nov 2, 2026

Study contacts

Barbara M Wirostko, MD
study director · Qlaris Bio

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QLS-111

Start the discussion